Omalizumab: A review of its use in patients with chronic spontaneous urticaria

Drugs

Volumn 74, Issue 14, 2014, Pages 1693-1699

  McCormack, Paul L ^a  

^a Springer Private Bag 65901 Mairangi Bay 0754 ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ANTIGEN ANTIBODY COMPLEX; ARTHRALGIA; ARTICLE; BACKACHE; BASOPHIL; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; COMPLEX FORMATION; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EOSINOPHIL; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC URTICARIA; IMMUNOGLOBULIN BLOOD LEVEL; INFECTIOUS COMPLICATION; INFESTATION; INJECTION SITE REACTION; MAST CELL; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OROPHARYNX PAIN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REMISSION; RHINOPHARYNGITIS; SINUS CONGESTION; SINUSITIS; SPRAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; VOLUME OF DISTRIBUTION; CHRONIC DISEASE;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC DISEASE; HUMANS; URTICARIA;

EID: 84910630233     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0290-9     Document Type: Article

References (18)

1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69(7):868-87.
2. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317-30.
3. Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2014. doi: 10.1016/j.jaci.2014.04.036.
4. Sabroe RA, Grattan CE, Francis DM, et al. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol. 1999;140(3):446-52.
5. McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013;73(11):1197-212.
6. European Medicines Agency. Xolair 150 mg powder/solution: summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000606/WC500057298.pdf. Accessed 3 Sep 2014.
7. Metz M, Maurer M. Omalizumab in chronic urticaria. Curr Opin Allergy Clin Immunol. 2012;12(4):406-11.
8. Saini S, Rosen KE, Hsieh H-J, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128(3):567-73.e1.
9. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128(1):202-9.e5.
10. Shin B, Kwon HS, Park SY, et al. Blood immunoglobulin E and eosinophil levels predict treatment response to omalizumab in refractory chronic urticaria [abstract no. P6-160]. Allergy. 2013;68(Suppl 98):36.
11. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.
12. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2014;. doi: 10.1038/jid.2014.306.
13. Maurer M, Rosen K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.[Erratum appears in N Engl J Med. 2013, 368(24), pp. 2340-1]. N Engl J Med. 2013;368(10):924-35.
14. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-9.
15. US FDA. Xolair (omalizumab): US prescribing information. 2003. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103976s5211lbl.pdf. Accessed 3 Sep 2014.
16. European Medicines Agency. Xolair (omalizumab) type II variation: assessment report. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000606/WC500164453.pdf. Accessed 3 Sep 2014.
17. Grattan CE, Humphreys F. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol. 2007;157(6):1116-23.
18. Lang DM. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema. Ann Allergy Asthma Immunol. 2014;112(4):276-9.